Loading
M3T01 is an antibody from Gamma Biotherapeutics that blocks Fas ligand to protect cancer-fighting T cells, in a phase 1 trial in advanced solid tumours.
M3T01 is the lead programme of Gamma Biotherapeutics, a monoclonal antibody against Fas ligand. It is being tested as monotherapy and with pembrolizumab and other systemic therapies in a phase 1 trial in advanced solid tumours, NCT06719362, sponsored by Providence Health & Services and recruiting since June 2025. The National Cancer Institute funds its clinical development through an SBIR award (1R44CA310416-01).
Neutralises Fas ligand (FasL), which tumours produce and which drives apoptosis of activated T cells, so that T cells survive to enter and attack the tumour.
1.M3T01 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"M3T01" OR ABSTRACT:"M3T01") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about M3T01, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/